{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T04:25:49Z","timestamp":1758860749641},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,2,5]],"date-time":"2014-02-05T00:00:00Z","timestamp":1391558400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s10067-014-2508-3","type":"journal-article","created":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T06:55:25Z","timestamp":1391496925000},"page":"329-333","source":"Crossref","is-referenced-by-count":7,"title":["Disease activity after the discontinuation of biological therapy in inflammatory rheumatic diseases"],"prefix":"10.1007","volume":"33","author":[{"given":"Gabriella","family":"K\u00e1d\u00e1r","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Bal\u00e1zs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogl\u00e1rka","family":"So\u00f3s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Laduver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Keszthelyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n","family":"Szekanecz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,2,5]]},"reference":[{"issue":"6","key":"2508_CR1","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Robert Landew\u00e9 R, Breedveld FC et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964\u2013975","journal-title":"Ann Rheum Dis"},{"key":"2508_CR2","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/ard.2009.117341","volume":"69","author":"B Saleem","year":"2010","unstructured":"Saleem B, Keen H, Goeb V et al (2010) Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 69:1636\u20131642","journal-title":"Ann Rheum Dis"},{"issue":"2 Suppl","key":"2508_CR3","first-page":"S126","volume":"58","author":"YP Goekoop-Ruiterman","year":"2008","unstructured":"Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al (2008) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 58(2 Suppl):S126\u2013S135","journal-title":"Arthritis Rheum"},{"key":"2508_CR4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/art.20712","volume":"52","author":"MA Quinn","year":"2005","unstructured":"Quinn MA, Conaghan PG, O\u2019Connor PJ et al (2005) Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo controlled trial. Arthritis Rheum 52:27\u201335","journal-title":"Arthritis Rheum"},{"key":"2508_CR5","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1136\/ard.2010.147751","volume":"70","author":"M Broek van den","year":"2011","unstructured":"van den Broek M, Klarenbeek NB, Dirven L et al (2011) Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 70:1389\u20131394","journal-title":"Ann Rheum Dis"},{"key":"2508_CR6","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/ard.2008.092254","volume":"68","author":"SM Kooij van der","year":"2009","unstructured":"van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK et al (2009) Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 68:914\u2013921","journal-title":"Ann Rheum Dis"},{"key":"2508_CR7","unstructured":"Kavanaugh A, Emery P, Fleischmann R, et al (2011) Withdrawal of adalimumab in early rheumatoid arthritis patients who attained stable low disease activity with adalimumab plus methotrexate: results of a phase 4, double-bind, placebo-controlled trial. ACR 2011, abstract No 1699"},{"key":"2508_CR8","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/ard.2009.121491","volume":"69","author":"Y Tanaka","year":"2010","unstructured":"Tanaka Y, Takeuchi T, Mimori T et al (2010) Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 69:1286\u20131291","journal-title":"Ann Rheum Dis"},{"key":"2508_CR9","unstructured":"Tanaka Y, Hirata S, Nawate M, et al (2011) Discontinuation of adalimumab without functional and structural progress after attaining remission in patients with rheumatoid arthritis (an interim report of HONOR study). ACR 2011 abstract No 2468"},{"key":"2508_CR10","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.autrev.2011.04.015","volume":"10","author":"MS Chimenti","year":"2011","unstructured":"Chimenti MS, Graceffa D, Perricone R (2011) Anti-TNF\u03b1 discontinuation in rheumatoid and psoriatic arthritis: is it possible after disease remission? Autoimmun Rev 10:636\u2013640","journal-title":"Autoimmun Rev"},{"key":"2508_CR11","doi-asserted-by":"crossref","first-page":"R439","DOI":"10.1186\/ar1693","volume":"7","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos X, Listing J, Brandt J et al (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7:R439\u2013R444","journal-title":"Arthritis Res Ther"},{"key":"2508_CR12","first-page":"342","volume":"44","author":"J Brandt","year":"2003","unstructured":"Brandt J, Khariouzou A, Listing J et al (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 44:342\u20133484","journal-title":"Arthritis Rheum"},{"key":"2508_CR13","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10067-011-1722-5","volume":"30","author":"V Navarro-Comp\u00e1n","year":"2011","unstructured":"Navarro-Comp\u00e1n V, Moreira V, Ariza-Ariza R et al (2011) Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol 30:993\u2013996","journal-title":"Clin Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2508-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-014-2508-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2508-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:57:31Z","timestamp":1559120251000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-014-2508-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,5]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["2508"],"URL":"https:\/\/doi.org\/10.1007\/s10067-014-2508-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,5]]}}}